73

Oncology
Prevention and treatment of tumors, and caring for cancer patients.
Sub Categories on Oncology
Latest Articles
Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

July 9, 2023Kyle DohertyThe addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared wit

Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

July 9, 2023Kyle DohertyThe addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared wit
Standard of care chemoradiation for stage III non-small cell lung cancer is superior to two tested alternatives

Standard of care chemoradiation for stage III non-small cell lung cancer is superior to two tested alternatives

by NRG OncologyCredit: CC0 Public DomainLung cancer is the leading cause of cancer death in the United States and approximately 75-80 percent of all cases are non-small cell lung cancer (NSCLC). Of th

Standard of care chemoradiation for stage III non-small cell lung cancer is superior to two tested alternatives

by NRG OncologyCredit: CC0 Public DomainLung cancer is the leading cause of cancer death in the United States and approximately 75-80 percent of all cases are non-small cell lung cancer (NSCLC). Of th
IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

August 13, 2023Kristi RosaSingle-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to da

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

August 13, 2023Kristi RosaSingle-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to da
“The power of science”: HPV vaccine proven to dramatically reduce cervical cancer

“The power of science”: HPV vaccine proven to dramatically reduce cervical cancer

byLilly Matson| Analysis3 November 2021Share this articleAlmost all cervical cancers are caused by the human papilloma virus (HPV), depicted above.After decades of research,the UK im

“The power of science”: HPV vaccine proven to dramatically reduce cervical cancer

byLilly Matson| Analysis3 November 2021Share this articleAlmost all cervical cancers are caused by the human papilloma virus (HPV), depicted above.After decades of research,the UK im
P53 could be key to therapies for salivary gland cancer

P53 could be key to therapies for salivary gland cancer

Mouse models show that activating a non-mutated form of the gene could lead to developing therapies for salivary gland cancer.Researchers at the University of Michigan Rogel Cancer Center and School o

P53 could be key to therapies for salivary gland cancer

Mouse models show that activating a non-mutated form of the gene could lead to developing therapies for salivary gland cancer.Researchers at the University of Michigan Rogel Cancer Center and School o
Multimodal sequencing achieves high-quality results from small volumes of frozen tumor specimens

Multimodal sequencing achieves high-quality results from small volumes of frozen tumor specimens

byColumbia University School of Engineering and Applied ScienceA Circos plot representing the results of matched T-cell receptor sequencing collected on a patient undergoing anti-PD1 therapy. Co

Multimodal sequencing achieves high-quality results from small volumes of frozen tumor specimens

byColumbia University School of Engineering and Applied ScienceA Circos plot representing the results of matched T-cell receptor sequencing collected on a patient undergoing anti-PD1 therapy. Co
Advancing Against Melanoma With Microneedles Technology

Advancing Against Melanoma With Microneedles Technology

byColleen Fleisson August 22, 2023A novel strategy that combines a painless, minimally invasivemicroneedleplatform with the ability to absorb biomarker-rich fluid from the skin

Advancing Against Melanoma With Microneedles Technology

byColleen Fleisson August 22, 2023A novel strategy that combines a painless, minimally invasivemicroneedleplatform with the ability to absorb biomarker-rich fluid from the skin
What Causes Blood Clots in Stool?

What Causes Blood Clots in Stool?

What Causes Blood Clots in Stool?ByPamela Assid, DNP, RNUpdated on November 01, 2023Medically reviewed byKimberly Brown, MDBlood clots in stool can have a number of possible ca

What Causes Blood Clots in Stool?

What Causes Blood Clots in Stool?ByPamela Assid, DNP, RNUpdated on November 01, 2023Medically reviewed byKimberly Brown, MDBlood clots in stool can have a number of possible ca
More proof that concurrent use of multiple medications leads to adversity for older cancer patients

More proof that concurrent use of multiple medications leads to adversity for older cancer patients

byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainWhen older adults with cancer take multiple medications—including ordinary drugs like blood pressure pills, supplements,

More proof that concurrent use of multiple medications leads to adversity for older cancer patients

byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainWhen older adults with cancer take multiple medications—including ordinary drugs like blood pressure pills, supplements,
Closing the loop to target brain glioblastomas

Closing the loop to target brain glioblastomas

by Joshua Stewart,Georgia Institute of TechnologyCredit:Science Advances(2022). DOI: 10.1126/sciadv.add2288"Closing the loop" has become one of the jargony cliches of the b

Closing the loop to target brain glioblastomas

by Joshua Stewart,Georgia Institute of TechnologyCredit:Science Advances(2022). DOI: 10.1126/sciadv.add2288"Closing the loop" has become one of the jargony cliches of the b
Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14, 2023Caroline SeymourNeoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic r

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14, 2023Caroline SeymourNeoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic r
Dietary selenium may help fight acute myeloid leukemia, researchers report

Dietary selenium may help fight acute myeloid leukemia, researchers report

by Chuck Gill,Pennsylvania State UniversityGraphical abstract. Credit:Cell Reports(2023). DOI: 10.1016/j.celrep.2023.112794Selenium-enriched diets may help ward off myeloid leukemia,

Dietary selenium may help fight acute myeloid leukemia, researchers report

by Chuck Gill,Pennsylvania State UniversityGraphical abstract. Credit:Cell Reports(2023). DOI: 10.1016/j.celrep.2023.112794Selenium-enriched diets may help ward off myeloid leukemia,